Research programme: RNAi therapeutics - Arbutus

Drug Profile

Research programme: RNAi therapeutics - Arbutus

Alternative Names: ARB-1740; LNP-siRNA therapeutics - Arbutus; TKM-ALDH; TKM-GSD; TKM-HTG; TKM-Marburg; WEE1/CSN5

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Gene therapies; Small interfering RNA
  • Mechanism of Action COPS5 protein inhibitors; RNA interference; WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Marburg virus disease

Highest Development Phases

  • Preclinical Alcoholism; Hepatitis B; Hypertriglyceridaemia; Lysosomal storage diseases; Marburg virus disease; Non-alcoholic steatohepatitis; Solid tumours

Most Recent Events

  • 11 Nov 2016 Preclinical data in Hepatitis B infections presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 12 Oct 2016 Research programme: RNAi therapeutics - Arbutus is available for licensing as of 12 Oct 2016.
  • 08 Aug 2016 Arbutus receives patent issuance for Lipid nanoparticle (LNP) delivery technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top